C2i Genomics

Genomic Expression's mission is to save lives and to make the delivery of healthcare more effective. The company helps doctors select the best drug for their patients, by leveraging it's clinically focused RNA sequencing technology called OneRNA. OneRNA can uniquely identify and quantify more than 34,000 RNA's in one assay and is currently undergoing beta testing by pharma companies and clinicians. Preliminary data suggests that the OneRNA assay may be suitable for determining response to the novel immune therapies including the PD1 checkpoint inhibitors.

Freenome is an AI genomics biotechnology company in South San Francisco, California. By using a blood test, Freenome can help detect and treat cancer quickly and efficiently.

20/20 GeneSystems has developed, validated, and undergone clinical testing of a blood test for the early detection of lung cancer. The test measures a panel of tumor biomarkers and utilizes a proprietary algorithm to combine the biomarker values to generate a unitary risk score.

OncoHost结合生命科学研究和亿旺资讯公司ed machine learning technology to develop personalized strategies to maximize the success of cancer therapy. Utilizing proprietary proteomic analysis, the company aims to understand patients' unique response to therapy and overcome one of the major obstacles in clinical oncology: resistance to therapy. OncoHost's host response profiling platform, PROphet®, analyzes proteomic changes in blood samples to monitor the dynamics of biological processes induced by the patient (i.e. the host) in response to a given cancer therapy. This proteomic profile is highly predictive of individual patient outcome, thus enabling personalized treatment planning. PROphet® also identifies potential drug targets, advancing the development of therapeutic strategies, as well as rationally-based combination therapies. The company was founded in 2017 and is based in Binyamina, Israel.

Biohope is dedicated to the development of diagnostic and therapeutic solutions for the immunological clinical management of kidney transplant patients, with potential application to other immune-based diseases.

Cellworks Group operates as a life sciences technology company. The company provides iC-PHYS, a technology platform that enables drug and biomarker discovery and research in focused therapeutic areas. The company is headquartered in South San Francisco, California.